Editorial: ustekinumab during pregnancy-reassuring but still not enough. Authors' reply
- PMID: 36468216
- DOI: 10.1111/apt.17282
Editorial: ustekinumab during pregnancy-reassuring but still not enough. Authors' reply
Comment on
-
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.Aliment Pharmacol Ther. 2022 Nov;56(9):1361-1369. doi: 10.1111/apt.17224. Epub 2022 Sep 27. Aliment Pharmacol Ther. 2022. PMID: 36168705
References
REFERENCES
-
- Brons G, Cranath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20(6):1091-8.
-
- Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734-57.e731.
-
- De Lima A, Zelinkova Z, van der Ent C, Steegers EAP, Van Der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65(8):1261-6.
-
- Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):145-62. e452.
-
- Avni-Biron I, Mishael T, Zittan E, Livne-Margolin M, Zinger A, Tzadok R, et al. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study. Aliment Pharmacol Ther. 2022;56:1361-1369.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources